acquired thrombotic thrombocytopenic purpura
acquired thrombotic thrombocytopenic purpura
Explore linked clinical trials. Standard reference: MONDO:00197405 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Retrospective Analysis of the Efficiency of Caplacizumab in the Treatment of aTTP | Cytopenia, Hemic and Lymphatic Diseases, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Skin Manifestations, acquired thrombotic thrombocytopenic purpura, blood coagulation disease, blood platelet disease, hematologic disorder, purpura, thrombocytopenia, thrombocytopenic purpura, thrombophilia, thrombotic microangiopathy, thrombotic thrombocytopenic purpura | Active, not recruiting | Not stated | 2026-04-30 | NCT04985318 | |
| Daratumumab in Immune-mediated Thrombotic Thrombocytopenic Purpura | Cytopenia, Hemic and Lymphatic Diseases, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Skin Manifestations, acquired thrombotic thrombocytopenic purpura, blood coagulation disease, blood platelet disease, hematologic disorder, purpura, thrombocytopenia, thrombocytopenic purpura, thrombophilia, thrombotic microangiopathy, thrombotic thrombocytopenic purpura | Recruiting | Not stated | 2026-04-14 | NCT07513948 | |
| Association of TNFAIP3 With Immune-mediated TTP | acquired thrombotic thrombocytopenic purpura | Recruiting | Not applicable | 2026-03-27 | NCT06928233 | |
| Improvement of Immunologic and Molecular Techniques for the Diagnosis and Follow-up of Patients With Thrombotic Thrombocytopenic Purpura | Cytopenia, Hemic and Lymphatic Diseases, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Skin Manifestations, acquired thrombotic thrombocytopenic purpura, blood coagulation disease, blood platelet disease, hematologic disorder, purpura, thrombocytopenia, thrombocytopenic purpura, thrombophilia, thrombotic microangiopathy, thrombotic thrombocytopenic purpura | Active, not recruiting | Not stated | 2026-02-11 | NCT05046717 | |
| BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases | Behcet disease, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Cytopenia, Hemic and Lymphatic Diseases, Hemorrhage, Immunoglobulin G4-Related Disease, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Sjogren syndrome, Skin Manifestations, Skin and Connective Tissue Diseases, Stomatognathic Diseases, Xerostomia, acquired thrombotic thrombocytopenic purpura, anterior uveitis, anti-neutrophil cytoplasmic antibody-associated vasculitis, antiphospholipid syndrome, arthritic joint disease, arthropathy, autoimmune disease, blood coagulation disease, blood platelet disease, cardiovascular disorder, connective tissue disorder, dry eye syndrome, eye disorder, hematologic disorder, hereditary disease, hereditary periodic fever syndrome, hereditary skin disorder, immune system disorder, lacrimal apparatus disorder, mouth disorder, muscle tissue disorder, musculoskeletal system disorder, myositis disease, necrotizing vasculitis, nervous system disorder, neuromuscular disease, panuveitis, purpura, rheumatic disorder, rheumatoid arthritis, salivary gland disorder, skin disorder, skin vascular disease, systemic lupus erythematosus, systemic sclerosis, thrombocytopenia, thrombocytopenic purpura, thrombophilia, thrombotic microangiopathy, thrombotic thrombocytopenic purpura, uveal disorder, uveitis, vascular disorder, vasculitis | Recruiting | Phase 2 | 2025-04-02 | NCT06794008 |